Introduction: Corrected QT (QTc) interval is an essential proarrhythmic risk biomarker, but recent data have identified limitations to its use. The J to T-peak (JTp) interval is an alternative biomarker for evaluating drug-induced proarrhythmic risk. The aim of this study was to evaluate pharmacological effects using spatial magnitude leads and DII electrocardiogram (ECG) leads and common ECG confounders (ie, stress and body temperature changes) on covariate adjusted QT (QTca), covariate adjusted JTp (JTpca), and covariate adjusted T-peak to T-end (Tpeca) intervals.
Methods: Beagle dogs were exposed to body hyper- (42 °C) or hypothermic (33 °C) conditions or were administered epinephrine to assess confounding effects on heart rate corrected QTca, JTpca, and Tpeca intervals. Dofetilide (0.1, 0.3, 1.0 mg/kg), ranolazine (100, 140, 200 mg/kg), and verapamil (7, 15, 30, 43, 62.5 mg/kg) were administered to evaluate pharmacological effects.
Results: Covariate adjusted QT (slope -12.57 ms/°C) and JTpca (-14.79 ms/°C) were negatively correlated with body temperature but Tpeca was minimally affected. Epinephrine was associated with QTca and JTpca shortening, which could be related to undercorrection in the presence of tachycardia, while minimal effects were observed for Tpeca. There were no significant ECG change following ranolazine administration. Verapamil decreased QTca and JTpca intervals and increased Tpeca, whereas dofetilide increased QTca and JTpca intervals but had inconsistent effects on Tpeca.
Conclusion: Results highlight potential confounders on QTc interval, but also on JTpca and Tpeca intervals in nonclinical studies. These potential confounding effects may be relevant to the interpretation of ECG data obtained from nonclinical drug safety studies with Beagle dogs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/1091581820954865 | DOI Listing |
Background: Pivotal Alzheimer's Disease (AD) trials typically require thousands of participants, resulting in long enrollment timelines and substantial costs. We leverage deep learning predictive models to create prognostic scores (forecasted control outcome) of trial participants and in combination with a linear statistical model to increase statistical power in randomized clinical trials (RCT). This is a straightforward extension of the traditional RCT analysis, allowing for ease of use in any clinical program.
View Article and Find Full Text PDFBackground: In Alzheimer's Disease (AD) trials, clinical scales are used to assess treatment effect in patients. Minimizing statistical uncertainty of trial outcomes is an important consideration to increase statistical power. Machine learning models can leverage baseline data to create AI-generated digital twins - individualized predictions (or prognostic scores) of how each patient's clinical outcomes may change during a trial assuming they received placebo.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Michigan, Ann Arbor, MI, USA.
Background: Studies link nature exposure to better cognitive health outcomes. However, little is known about which types or 'how much' of nature is needed for health benefits. Studies often lack diverse aging populations and have small sample sizes.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Pennsylvania, School of Nursing, Philadelphia, PA, USA.
Background: Behavioral variant Frontotemporal Degeneration (bvFTD) is a common form of early onset dementia characterized by prominent behavioral change, including loss of empathy. Research has demonstrated that caregivers of persons living with bvFTD (PLwFTD) are more burdened, stressed, and depressed than other dementia caregivers, and that empathy loss may contribute to this high level of burden. However, it remains unclear if empathy loss contributes to caregiver burden above and beyond other neuropsychiatric symptoms.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.
Background: Promising elements of assistive technologies are available to help people with cognitive impairment in their daily lives. However, there has been limited research on how smartwatches can directly interact with persons who have cognitive impairments. We looked at the factors that affect the effectiveness of interventions provided via a smartwatch.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!